Logo image of ALCJ.PA

CROSSJECT (ALCJ.PA) Stock Fundamental Analysis

EPA:ALCJ - Euronext Paris - Matif - FR0011716265 - Common Stock - Currency: EUR

1.82  +0.05 (+3.06%)

Fundamental Rating

2

Overall ALCJ gets a fundamental rating of 2 out of 10. We evaluated ALCJ against 60 industry peers in the Health Care Equipment & Supplies industry. ALCJ may be in some trouble as it scores bad on both profitability and health. ALCJ is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALCJ has reported negative net income.
ALCJ had a negative operating cash flow in the past year.
In the past 5 years ALCJ always reported negative net income.
ALCJ had a negative operating cash flow in each of the past 5 years.
ALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -31.63%, ALCJ is doing worse than 80.00% of the companies in the same industry.
With a Return On Equity value of -593.99%, ALCJ is not doing good in the industry: 85.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -31.63%
ROE -593.99%
ROIC N/A
ROA(3y)-32.8%
ROA(5y)-31.4%
ROE(3y)-377.91%
ROE(5y)-284%
ROIC(3y)N/A
ROIC(5y)N/A
ALCJ.PA Yearly ROA, ROE, ROICALCJ.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

ALCJ has a Gross Margin of 993.79%. This is amongst the best in the industry. ALCJ outperforms 100.00% of its industry peers.
ALCJ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 993.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCJ.PA Yearly Profit, Operating, Gross MarginsALCJ.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

ALCJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALCJ has more shares outstanding
The number of shares outstanding for ALCJ has been increased compared to 5 years ago.
ALCJ has a worse debt/assets ratio than last year.
ALCJ.PA Yearly Shares OutstandingALCJ.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
ALCJ.PA Yearly Total Debt VS Total AssetsALCJ.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

ALCJ has an Altman-Z score of 0.25. This is a bad value and indicates that ALCJ is not financially healthy and even has some risk of bankruptcy.
ALCJ has a worse Altman-Z score (0.25) than 71.67% of its industry peers.
A Debt/Equity ratio of 11.67 is on the high side and indicates that ALCJ has dependencies on debt financing.
ALCJ has a worse Debt to Equity ratio (11.67) than 86.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 11.67
Debt/FCF N/A
Altman-Z 0.25
ROIC/WACCN/A
WACC7.24%
ALCJ.PA Yearly LT Debt VS Equity VS FCFALCJ.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

ALCJ has a Current Ratio of 1.58. This is a normal value and indicates that ALCJ is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ALCJ (1.58) is comparable to the rest of the industry.
A Quick Ratio of 0.89 indicates that ALCJ may have some problems paying its short term obligations.
The Quick ratio of ALCJ (0.89) is worse than 61.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 0.89
ALCJ.PA Yearly Current Assets VS Current LiabilitesALCJ.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ALCJ have decreased by -1.92% in the last year.
The Revenue for ALCJ has decreased by -71.00% in the past year. This is quite bad
EPS 1Y (TTM)-1.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.25%
Revenue 1Y (TTM)-71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 39.59% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 68.53% on average over the next years. This is a very strong growth
EPS Next Y26.77%
EPS Next 2Y57.1%
EPS Next 3Y53.15%
EPS Next 5Y39.59%
Revenue Next Year3.06%
Revenue Next 2Y105.3%
Revenue Next 3Y81.25%
Revenue Next 5Y68.53%

3.3 Evolution

ALCJ.PA Yearly Revenue VS EstimatesALCJ.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
ALCJ.PA Yearly EPS VS EstimatesALCJ.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCJ. In the last year negative earnings were reported.
ALCJ is valuated reasonably with a Price/Forward Earnings ratio of 10.79.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALCJ indicates a rather cheap valuation: ALCJ is cheaper than 88.33% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.15, ALCJ is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 10.79
ALCJ.PA Price Earnings VS Forward Price EarningsALCJ.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCJ.PA Per share dataALCJ.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

ALCJ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALCJ's earnings are expected to grow with 53.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.1%
EPS Next 3Y53.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALCJ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CROSSJECT

EPA:ALCJ (5/30/2025, 7:00:00 PM)

1.82

+0.05 (+3.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)09-22 2025-09-22
Inst Owners0.4%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap84.14M
Analysts84.44
Price Target3.93 (115.93%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.94%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-9.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.79
P/S 580.27
P/FCF N/A
P/OCF N/A
P/B 47.7
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)0.17
Fwd EY9.27%
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.04
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.63%
ROE -593.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 993.79%
FCFM N/A
ROA(3y)-32.8%
ROA(5y)-31.4%
ROE(3y)-377.91%
ROE(5y)-284%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 11.67
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 168.89%
Cap/Sales 3028.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 0.89
Altman-Z 0.25
F-Score3
WACC7.24%
ROIC/WACCN/A
Cap/Depr(3y)152.85%
Cap/Depr(5y)140.85%
Cap/Sales(3y)1954.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.25%
EPS Next Y26.77%
EPS Next 2Y57.1%
EPS Next 3Y53.15%
EPS Next 5Y39.59%
Revenue 1Y (TTM)-71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year3.06%
Revenue Next 2Y105.3%
Revenue Next 3Y81.25%
Revenue Next 5Y68.53%
EBIT growth 1Y6.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.64%
EBIT Next 3Y59.57%
EBIT Next 5Y44.67%
FCF growth 1Y-6.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.91%
OCF growth 3YN/A
OCF growth 5YN/A